MedTrace Logo

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

NCT00032929 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 269

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.

Conditions

  • Cocaine-Related Disorders

Interventions

DRUG

Selegiline

Sponsors & Collaborators

  • Somerset Pharmaceuticals

    collaborator INDUSTRY

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Ahmed Elkashef, MD · National Institute on Drug Abuse (NIDA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2002-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00032929 on ClinicalTrials.gov